A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity
PHASE1CompletedINTERVENTIONAL
Enrollment
72
Participants
Timeline
Start Date
August 26, 2024
Primary Completion Date
April 3, 2025
Study Completion Date
April 3, 2025
Conditions
Weight Management
Interventions
DRUG
ASC30
Tablet, QD
OTHER
Placebo
Tablets, QD
Trial Locations (1)
84124
Ascletis clinical site, Salt Lake City
All Listed Sponsors
lead
Ascletis Pharma (China) Co., Limited
INDUSTRY
NCT06680440 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity | Biotech Hunter | Biotech Hunter